{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:10Z","timestamp":1783075930786,"version":"3.54.6"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1097\/jcp.0b013e31818ba2f6","type":"journal-article","created":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T08:12:22Z","timestamp":1226477542000},"page":"608-617","source":"Crossref","is-referenced-by-count":41,"title":["Striatal and Extrastriatal D2\/D3-Receptor-Binding Properties of Ziprasidone"],"prefix":"10.1097","volume":"28","author":[{"given":"Ingo","family":"Vernaleken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fellows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"Janouschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anno","family":"Br\u00f6cheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Veselinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Landvogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Boy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Spreckelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cumming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","article-title":"Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.","volume":"25","author":"Potkin","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4088\/JCP.v63n0609","article-title":"A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.","volume":"63","author":"Hirsch","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.","volume":"161","author":"Simpson","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(99)00005-9","article-title":"Pharmacological profile of neuroleptics at human monoamine transporters.","volume":"368","author":"Tatsumi","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02244926","article-title":"Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.","volume":"112","author":"Bench","year":"1993","journal-title":"Psychopharmacology"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pnpbp.2004.10.010","article-title":"Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.","volume":"2","author":"Corripio","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0893-133X(01)00251-2","article-title":"Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.","volume":"25","author":"Mukherjee","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R11-4-20210128","first-page":"964","article-title":"Parametric mapping of binding in human brain of D2 receptor ligands of different affinities.","volume":"46","author":"Siessmeier","year":"2005","journal-title":"J Nucl Med"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1016\/j.bmc.2007.07.017","article-title":"In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.","volume":"15","author":"Stark","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.","volume":"33","author":"Nordstrom","year":"1993","journal-title":"Biol Psychiatry"},{"issue":"suppl 1","key":"R16-4-20210128","first-page":"88","article-title":"The temporal and extrastriatal D2\/D3 receptor binding profile of aripiprazole in patients with schizophrenia.","volume":"31","author":"Grunder","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1301108","article-title":"Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.","volume":"31","author":"Kessler","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(05)63079-6","article-title":"Limbic selectivity of clozapine.","volume":"350","author":"Pilowsky","year":"1997","journal-title":"Lancet"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s002130000435","article-title":"Striatal and temporal cortical D2\/D3 receptor occupancy by olanzapine and sertindole in vivo: a 123Iepidepride single photon emission tomography (SPET) study.","volume":"150","author":"Bigliani","year":"2000","journal-title":"Psychopharmacology"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative 123Iepidepride SPET study of amisulpride-treated patients.","volume":"160","author":"Bressan","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"6","key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1176\/appi.ajp.158.6.926","article-title":"No support for regional selectivity in clozapine-treated patients: a PET study with (11)Craclopride and (11)CFLB 457.","volume":"158","author":"Talvik","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.npp.1300931","article-title":"The striatal and extrastriatal D2\/D3 receptor-binding profile of clozapine in patients with schizophrenia.","volume":"31","author":"Grunder","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145704004353","article-title":"High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.","volume":"7","author":"Vernaleken","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(25)21208-3","article-title":"Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.","volume":"279","author":"Fischman","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.","volume":"18","author":"Goff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology"},{"key":"R27-4-20210128","first-page":"109","article-title":"Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride.","volume":"44","author":"Grunder","year":"2003","journal-title":"J Nucl Med"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.ftd.0000150879.36296.4d","article-title":"Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.","volume":"27","author":"Sachse","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies.","volume":"4","author":"Lammertsma","year":"1996","journal-title":"NeuroImage"},{"issue":"suppl 1","key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1046\/j.1365-2125.2000.00148.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.","volume":"49","author":"Wilner","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0006-3223(89)90036-X","article-title":"Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.","volume":"26","author":"Chang","year":"1989","journal-title":"Biol Psychiatry"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0020-708X(85)90083-3","article-title":"Preparation of 11C-labelled raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey.","volume":"36","author":"Ehrin","year":"1985","journal-title":"Int J Appl Radiat Isot"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and 11Craclopride.","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.179.6.503","article-title":"Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.","volume":"179","author":"Xiberas","year":"2001","journal-title":"Br J Psychiatry"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an 18Ffallypride PET study.","volume":"165","author":"Grunder","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10673220701679812","article-title":"Neuroreceptor imaging studies in schizophrenia.","volume":"15","author":"Frankle","year":"2007","journal-title":"Harv Rev Psychiatry"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050420","article-title":"A PET-study of 11CFLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.","volume":"133","author":"Farde","year":"1997","journal-title":"Psychopharmacology"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.npp.1301242","article-title":"Striatal vs extrastriatal dopamine D2 receptors in antipsychotic responsea double-blind PET study in schizophrenia.","volume":"32","author":"Agid","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.npp.1300836","article-title":"Occupancy of striatal and extrastriatal dopamine D2\/D3 receptors by olanzapine and haloperidol.","volume":"30","author":"Kessler","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R42-4-20210128","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1006\/nimg.2001.0879","article-title":"Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-a simulation study based on experimental data.","volume":"14","author":"Olsson","year":"2001","journal-title":"NeuroImage"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.neuroimage.2006.11.003","article-title":"123Iepidepride binding to cerebellar dopamine D2\/D3 receptors is displaceable: implications for the use of cerebellum as a reference region.","volume":"34","author":"Pinborg","year":"2007","journal-title":"NeuroImage"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.mp.4001009","article-title":"Significant dissociation of brain and plasma kinetics with antipsychotics.","volume":"7","author":"Tauscher","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics.","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002139900333","article-title":"Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels.","volume":"149","author":"Fitzgerald","year":"2000","journal-title":"Psychopharmacology"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(96)00218-7","article-title":"A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.","volume":"16","author":"Nyberg","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"L103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci"},{"key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02251280","article-title":"5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.","volume":"110","author":"Nyberg","year":"1993","journal-title":"Psychopharmacology"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02245614","article-title":"The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.","volume":"124","author":"Bench","year":"1996","journal-title":"Psychopharmacology"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.neuroimage.2005.11.014","article-title":"Modulation of 18Ffluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.","volume":"30","author":"Vernaleken","year":"2006","journal-title":"NeuroImage"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1126\/science.847477","article-title":"Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.","volume":"196","author":"Burt","year":"1977","journal-title":"Science"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology"},{"key":"R56-4-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.107.121525","article-title":"Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.","volume":"322","author":"Summerfield","year":"2007","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31818ba2f6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T18:00:11Z","timestamp":1738519211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200812000-00004"}},"subtitle":["A Positron Emission Tomography Study With [18F]Fallypride and [11C]Raclopride (D2\/D3-Receptor Occupancy of Ziprasidone)"],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31818ba2f6","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}